Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 2431 AL 2445

Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography

Rosenberg PB, Wong DF, Edell SL, Ross JS, Joshi AD, Brašić JR, Zhou Y, Raymont V, Kumar A, Ravert HT, Dannals RF, Pontecorvo MJ, Skovronsky DM, Lyketsos CG.

Am J Geriatr Psychiatry. 2013 Mar;21(3):272-8. doi: 10.1016/j.jagp.2012.11.016.

Genetic study of neurexin and neuroligin genes in Alzheimer's disease

Martinez-Mir A, González-Pérez A, Gayán J, Antúnez C, Marín J, Boada M, Lopez-Arrieta JM, Fernández E, Ramírez-Lorca R, Sáez ME, Ruiz A, Scholl FG, Real LM.

J Alzheimers Dis. 2013;35(2):403-12. doi: 10.3233/JAD-122257.

Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer's disease

Perneczky R, Guo LH, Kagerbauer SM, Werle L, Kurz A, Martin J, Alexopoulos P.

Transl Psychiatry. 2013 Feb 19;3(2):e227. doi: 10.1038/tp.2013.11.

A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: replication in elderly and young populations

Roussotte FF, Jahanshad N, Hibar DP, Sowell ER, Kohannim O, Barysheva M, Hansell NK, McMahon KL, de Zubicaray GI, Montgomery GW, Martin NG, Wright MJ, Toga AW, Jack CR Jr, Weiner MW, Thompson PM; ADNI.

Hum Brain Mapp. 2014 Apr;35(4):1226-36. doi: 10.1002/hbm.22247. Epub 2013 Feb 21.

Imaging epigenetics in Alzheimer's disease

Lista S, Garaci FG, Toschi N, Hampel H.

Curr Pharm Des. 2013;19(36):6393-415. doi: 10.2174/13816128113199990370.

Cholinergic markers in the cortex and hippocampus of some animal species and their correlation to Alzheimer's disease

Orta-Salazar E, Cuellar-Lemus CA, Díaz-Cintra S, Feria-Velasco AI.

Neurologia. 2014 Oct;29(8):497-503. doi: 10.1016/j.nrl.2012.10.007. Epub 2013 Feb 22.

Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI

Vos SJ, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Frisoni GB, Froelich L, Nobili F, van der Flier W, Blennow K, Wolz R, Scheltens P, Visser PJ.

Neurology. 2013 Mar 19;80(12):1124-32. doi: 10.1212/WNL.0b013e318288690c. Epub 2013 Feb 27.

Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model

Cuadrado-Tejedor M, Ricobaraza AL, Torrijo R, Franco R, Garcia-Osta A.

Curr Pharm Des. 2013;19(28):5076-84. doi: 10.2174/1381612811319280006.

[Posterior variant of Alzheimer's disease and other atypical symptom pictures]

Remes AM, Vanninen R, Jokinen H, Hallikainen M, Erkinjuntti T.

Duodecim. 2013;129(3):244-50.

Alzheimer's disease drug development: translational neuroscience strategies

Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Walsh RR, Zhong K.

CNS Spectr. 2013 Jun;18(3):128-38. doi: 10.1017/S1092852913000023. Epub 2013 Mar 11.

Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease

Leclerc B, Abulrob A.

ScientificWorldJournal. 2013;2013:589308. doi: 10.1155/2013/589308. Epub 2013 Feb 5.

The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?

Papaliagkas VT.

Recent Pat CNS Drug Discov. 2013 Apr;8(1):70-8. doi: 10.2174/1574889811308010006.

Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease

Rosén C, Zetterberg H.

Curr Opin Psychiatry. 2013 May;26(3):276-82. doi: 10.1097/YCO.0b013e32835f6747.

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers

Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM.

Clin Chem. 2013 Jun;59(6):903-16. doi: 10.1373/clinchem.2013.202937. Epub 2013 Mar 21.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias